Abstract: A method of making a molecular sieve may include: reacting a source selected from the group consisting of: a source of a tetrahedral element in the presence of a structure directing agent (SDA) selected from the group consisting of: Ar+-L-Ar, Ar+-L-Ar-L-Ar+, Ar+-L-Ar-L-NR3+, and ArAr+-L-Ar+Ar, where Ar+ is to a N-containing cationic aromatic ring, Ar is to a non-charged aromatic ring, L is a methylene chain of 3-6 carbon atoms, NR3+ is to a quaternary ammonium, and ArAr+ and Ar+Ar are a fused aromatic ring structure comprising both a N-containing cationic portion and a non-charged portion, to produce the molecular sieve.

Abstract: A method of making a molecular sieve may include: reacting a source selected from the group consisting of: a source of a tetrahedral element in the presence of a structure directing agent (SDA) selected from the group consisting of: Ar+-L-Ar, Ar+-L-Ar-L-Ar+, Ar+-L-Ar-L-NR3+, and ArAr+-L-Ar+Ar, where Ar+ is to a N-containing cationic aromatic ring, Ar is to a non-charged aromatic ring, L is a methylene chain of 3-6 carbon atoms, NR3+ is to a quaternary ammonium, and ArAr+ and Ar+Ar are a fused aromatic ring structure comprising both a N-containing cationic portion and a non-charged portion, to produce the molecular sieve.

Abstract: A composition can include a Rho zeolite with a RHO topology having a Si to B ratio or a Si to Al ratio greater than or equal to 8. Making such a composition can include heating an aqueous reaction mixture having a molar ratio of atomic Si to atomic B of about 4 to about 50 or a molar ratio of atomic Si to atomic Al of about 4 to about 50 in the presence of a C4-C6 diquat of N,2-dimethylbenzimidazole structure directing agent to a temperature of at least 75° C. to produce a Rho zeolite.

Abstract: A method of making a molecular sieve may include: reacting a source selected from the group consisting of: a source of a tetrahedral element in the presence of a structure directing agent (SDA) selected from the group consisting of: Ar+-L-Ar, Ar+-L-Ar-L-Ar+, Ar+-L-Ar-L-NR3+, and ArAr+-L-Ar+Ar, where Ar+ is to a N-containing cationic aromatic ring, Ar is to a non-charged aromatic ring, L is a methylene chain of 3-6 carbon atoms, NR3+ is to a quaternary ammonium, and ArAr+ and Ar+Ar are a fused aromatic ring structure comprising both a N-containing cationic portion and a non-charged portion, to produce the molecular sieve.

Abstract: A composition can include a Rho zeolite with a RHO topology having a Si to B ratio or a Si to A1 ratio greater than or equal to 8. Making such a composition can include heating an aqueous reaction mixture having a molar ratio of atomic Si to atomic B of about 4 to about 50 or a molar ratio of atomic Si to atomic Al of about 4 to about 50 in the presence of a C4-C6 diquat of N,2-dimethylbenzimidazole structure directing agent to a temperature of at least 75° C. to produce a Rho zeolite.

Abstract: The zeolite UTD-1 may be formed under hydrothermal synthesis conditions using a directing agent that does not include a metal atom therein. Methods for synthesizing the zeolite UTD-1 may comprise: combining at least a silicon atom source and a directing agent having a structure of in an aqueous medium; forming the zeolite in the aqueous medium under hydrothermal synthesis conditions, such that the zeolite has a framework silicate with a cationic portion of the directing agent occluded within pores or channels of the framework silicate; and isolating the zeolite from the aqueous medium. The zeolite has a powder x-ray diffraction pattern with at least the following 2?scattering angles: 6.0±0.12, 7.6±0.1, 14.66±0.15, 19.7±0.15, 21.27±0.15, 22.13±0.15, 22.61±0.15, and 24.42±0.10 for a borosilicate form zeolite, or 6.0±0.12, 7.6±0.15, 14.55±0.15, 19.64±0.15, 21.01±0.20, 21.90±0.20, 22.34±0.20, and 24.38±0.20 for an aluminosilicate form zeolite.

Abstract: The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: The zeolite UTD-1 may be formed under hydrothermal synthesis conditions using a directing agent that does not include a metal atom therein. Methods for synthesizing the zeolite UTD-1 may comprise: combining at least a silicon atom source and a directing agent having a structure of in an aqueous medium; forming the zeolite in the aqueous medium under hydrothermal synthesis conditions, such that the zeolite has a framework silicate with a cationic portion of the directing agent occluded within pores or channels of the framework silicate; and isolating the zeolite from the aqueous medium. The zeolite has a powder x-ray diffraction pattern with at least the following 2?scattering angles: 6.0±0.12, 7.6±0.1, 14.66±0.15, 19.7±0.15, 21.27±0.15, 22.13±0.15, 22.61±0.15, and 24.42±0.10 for a borosilicate form zeolite, or 6.0±0.12, 7.6±0.15, 14.55±0.15, 19.64±0.15, 21.01±0.20, 21.90±0.20, 22.34±0.20, and 24.38 ±0.20 for an aluminosilicate form zeolite.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: The disclosure is related to EMM-37 materials, processes of making, and uses of the same as well as structure directing agents useful for the preparation of the EMM-37 materials, processes and intermediates for making such structure directing agents.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.

Abstract: A process for synthesizing a DDR framework-type molecular sieve comprises crystallizing a reaction mixture comprising water, a source of silicon, and a structure directing agent, Q, selected from the group consisting of a methyltropinium salt, a 2,6,N,N-tetramethylpiperidinium salt, a 2,N,N-trimethylpiperidinium salt and mixtures thereof, wherein the reaction mixture has a molar ratio of water to silicon from 5 to 80 and a molar ratio of alkali or alkaline earth metal, M, to silicon less than 0.01.

Abstract: A process for synthesizing a DDR framework-type molecular sieve comprises crystallizing a reaction mixture comprising water, a source of silicon, and a structure directing agent, Q, selected from the group consisting of a methyltropinium salt, a 2,6,N,N-tetramethylpiperidinium salt, a 2,N,N-trimethylpiperidinium salt and mixtures thereof, wherein the reaction mixture has a molar ratio of water to silicon from 5 to 80 and a molar ratio of alkali or alkaline earth metal, M, to silicon less than 0.01.

Abstract: Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.

Abstract: The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

Abstract: The present invention is directed to substituted propylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Abstract: The present invention is directed to benzothiadiazolylphenylalkylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Abstract: Compounds of formula I, wherein R1-R9 and n are defined herein, and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R3-R5, R10, and R11 are defined herein.